Indivior Pharmaceuticals (INDV) Cash from Operations Growth (1y) (2025 - 2026)
Indivior Pharmaceuticals (INDV) Cash from Operations Growth (1y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 425.00% |
| 10 | Indivior Pharmaceuticals | 5.05 Bn | 4.87 Bn | 277.00 Mn | -112.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112.00% |
| Dec 31, 2025 | -1,200.00% |
| Sep 30, 2025 | -2,050.00% |
| Jun 30, 2025 | 79.55% |
| Mar 31, 2025 | 302.70% |